rationale behind the watch and wait strategy in smoldering myeloma
Published 1 year ago • 834 plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
3:05
the rationale behind the myeloma uk clinical trial network
-
3:37
smoldering myeloma: state of the art
-
2:44
myeloma qol through induction and maintenance
-
5:20
approaching smoldering myeloma
-
2:11
overview and rationale for practical workshops at the 2016 european multiple myeloma academy (emma)
-
21:38
drawing the line: the rationale behind blood tube collection order
-
9:25
mgus diagnosis: a step-by-step approach
-
5:13
what is a haematologist?
-
1:01
car-t: myeloma toxicities
-
0:52
is there a role for combination therapy in cml?
-
2:17
extended follow-up of the master trial
-
1:53
the future of multiple myeloma treatment
-
4:29
smoldering myeloma: monitoring patients and deciding when to treat
-
0:52
novel strategies to evaluate biomarkers of interest in multiple myeloma
-
1:03
insights into the cartitude-6 trial: rationale and design
-
2:17
moving towards fixed-duration treatment in multiple myeloma
-
2:46
managing patients with high-risk myeloma
-
2:00
the incorporation of immunotherapy into frontline all treatment
-
1:24
highlights from the 2016 european multiple myeloma academy (emma) and overview of emma 2017
-
2:02
rwd from insight-mm: duration of therapy and treatment sequencing
-
1:59
outcomes from myeloma xi - what do the results tell us?